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Summary  The  penetration  rate  of  devices  in  general,  and  in  transcatheter  aortic  valve
replacement  (TAVR)  speciﬁcally,  is  signiﬁcantly  delayed  in  the  United  States  of  America  (USA)
compared  with  in  Europe.  This  is  mostly  due  to  the  mission  statement  of  the  regulatory  agencies
in  the  USA,  which  requires  very  rigorous  clinical  testing  of  a  device  prior  to  its  approval.  The
USA  had  a  major  role  in  the  development  and  evaluation  of  this  technology  and  USA  research
has  enabled  clinicians  inside  and  outside  of  the  USA  to  conduct  a  concise  scientiﬁcally  based
assessment  of  the  performance  of  TAVR  devices  in  terms  of  safety  and  efﬁcacy.  In  the  following
review,  we  provide  data  on  the  development  of  TAVR  in  the  USA,  revealing  the  critical  role  the
USA  has  played  in  this  extraordinary  process.
©  2012  Elsevier  Masson  SAS.  
MOTS  CLÉS Résumé  La  pénétration  des  dispositifs  médicaux  et  des  valves  aortiques  percutanées  en  parti-
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culier  est  retardée  aux  États-Unis  comparé  à  l’Europe.  Cela  est  essentiellement  lié  au  processus
réglementaires  de  régulation  aux  États-Unis  qui  requiert  une  évaluation  clinique  très  rigoureuse
avant  approbation  des  dispositifs.  Les  États-Unis  ont  joué  un  rôle  majeur  dans  le  développe-
ment de  cette  technologie  et  l’évaluation  scientiﬁque  a  permis  aux  cliniciens  à  travers  le
monde  d’obtenir  une  évaluation  concise  « basée sur  les  preuves  » de  la  performance  des  valves
percutanées  en  termes  de  sécurité  et  d’efﬁcacité.  Nous  allons  dans  cette  mise  au  point,  décrire
Abbreviations: AS, aortic stenosis; CE, conformité européenne; FDA, Food and Drug Administration; PAS, postapproval study; SAVR,
urgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; USA, United States of America.
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le  développement  des  valves  aortiques  percutanées  aux  USA,  et  le  rôle  majeur  joué  par  les
États-Unis  dans  cet  extraordinaire  aventure  « process  ».
© 2012  Elsevier  Masson  SAS.  
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a signiﬁcant  degree  of  clinical  complexity  and  adverse
Cet article est publié en Open Access sous licence CC BY-NC-ND.Background
It  is  now  10  years  since  the  ﬁrst  human  transcatheter  aortic
valve replacement  (TAVR),  a  procedure  performed  in  Rouen,
France, in  a  patient  with  severe  aortic  stenosis  (AS)  [1].
Currently, a  decade  after  this  historic  event,  most  TAVR
procedures performed  and  the  majority  of  innovations  in
the ﬁeld  of  transcatheter  valve  technologies  occur  outside
the United  States  of  America  (USA).  Nevertheless,  the  USA
had a  major  role  in  the  development  and  evaluation  of  this
technology (Fig.  1).  It  could  be  said  that  although  TAVR
was born  in  France,  it  matured  in  the  USA.  In  the  following
review, we  provide  data  on  the  development  of  TAVR  in
the USA,  revealing  the  critical  role  the  USA  played  in  this
extraordinary process.
The early days
In  early  2004,  almost  2  years  after  the  ﬁrst  human  TAVR
procedure, when  only  a  total  of  17  patients  had  been
treated by  this  technology,  TAVR  entered  into  the  ‘major
league’ of  the  industry  with  the  purchase  of  a  small
privately held  medical  technology  company,  Percutaneous
Valve Technologies,  Inc.  (PVT,  Caesarea,  Israel),  by  the
American-born Edwards  Lifesciences  Corporation  (Irvine,
CA, USA).  This  transaction  allowed  Edwards  to  accelerate
the development  of  this  breakthrough  technology  while
providing the  needed  expertise  and  resources  to  ensure  suc-
cessful  commercialization  (Fig.  2).  Several  months  later,  at
the 2004  Transcatheter  Cardiovascular  Therapeutics  (TCT)
Figure 1. Milestones in the development of transcatheter aortic valve
o
a
geeting  held  in  Washington,  DC,  TAVR  attracted  major
ublicity as  a  widely  discussed  topic.  One  of  the  highlights
as the  live  introduction  of  a  patient  1-year  post-TAVR.
easibility evaluation of the Edwards
APIEN  device
he  USA  Food  and  Drug  Administration  (FDA)  had  a  major
nﬂuence on  the  evaluation  of  TAVR  devices.  The  FDA,  an
gency within  the  United  States  Department  of  Health  and
uman Services,  is  responsible  for  protecting  and  promoting
ublic health  through  the  regulation  and  supervision  of
umerous materials,  including  medical  devices.  The  Center
or Devices  and  Radiological  Health  is  the  branch  of  the
DA responsible  for  the  premarket  approval  of  all  medical
evices in  the  USA,  as  well  as  overseeing  the  manufactur-
ng, performance  and  safety  of  these  devices.  In  January
005, the  FDA  conditionally  approved  the  ﬁrst  feasibility
rial of  the  Cribier-Edwards  percutaneous  aortic  heart
alve. Six  months  later,  Edwards  Lifesciences  announced  a
elay in  enrolment  in  its  percutaneous  aortic  heart  valve
linical feasibility  trials  in  the  USA  using  the  antegrade
ransseptal delivery,  in  order  to  incorporate  the  retrograde
elivery system,  which  at  that  time  had  already  been
valuated in  several  cases  in  Canada.  The  company  took
his action  after  some  USA  antegrade  cases  demonstrated devices in the USA and in Europe.
utcomes. However,  the  ‘loss’  of  the  antegrade  transseptal
pproach was  rapidly  replaced  that  year  by  the  ante-
rade transapical  approach,  performed  using  the  Ascendra
162  
F
s
o
C
r
p
H
U
C
2
a
T
t
I
o
r
o
t
t
t
o
E
a
a
c
(
s
s
t
a
t
t
t
r
t
2
w
F
E
m
c
r
r
c
t
a
w
c
a
a
i
t
B
b
d
a
o
d
m
i
w
T
s
t
A
s
s
t
h
i
a
p
p
m
o
w
p
v
i
p
a
w
w
I
i
d
r
c
F
a
On  20  July  2011,  the  FDA  Circulatory  System  Devices  Paneligure 2. Edwards SAPIEN device in preparation.
ystem.  Later  that  year,  the  FDA  approved  the  re-enrolment
f 20  patients  in  a  non-randomized  feasibility  trial  of  its
ribier-Edwards percutaneous  aortic  heart  valve  using  the
etrograde transfemoral  approach.  This  pioneering  trial  took
lace at  three  clinical  sites  in  the  USA  (William  Beaumont
ospital, Royal  Oak,  MI;  New  York-Presbyterian/Columbia
niversity  Medical  Center,  New  York,  NY;  and  The  Cleveland
linic Foundation,  Cleveland,  OH).  From  January  to  May
006, the  three  centres  completed  20  cases.  The  FDA  then
pproved the  enrolment  of  an  additional  35  patients.
he PARTNER (Placement of AoRTic
raNscathetER  valves) trial
n  March  2007,  after  submitting  follow-up  data  from  the
riginal 55-patient  feasibility  study,  Edwards  Lifesciences
eceived approval  from  the  FDA  to  initiate  a  pivotal  trial
f its  Edwards  SAPIEN  transcatheter  aortic  heart  valve
echnology —  the  PARTNER  trial  (Placement  of  AoRTic
raNscathetER  valves).  This  trial  was  a  randomized  con-
rolled multicentre  study  that  assigned  patients  into  one
f two  arms:  a  ‘non-surgical’  arm  (Cohort  B),  in  which  the
dwards SAPIEN  valve  was  compared  with  medical  therapy
nd balloon  valvuloplasty  at  the  operator’s  discretion;
nd a  ‘surgical’  arm  (Cohort  A),  in  which  the  device  was
ompared with  traditional  surgical  aortic  valve  replacement
SAVR). The  trial  began  enrolment  initially  at  two  study
ites that  were  part  of  the  earlier  transfemoral  feasibility
tudy. This  rapidly  expanded  to  another  15  study  sites  in
he USA.  One  year  later,  Edwards  Lifesciences  received  FDA
pproval to  add  the  Ascendra  transapical  delivery  system
o the  PARTNER  trial  and  also  received  approval  to  increase
he trial  sample  size  from  600  to  1040  patients.  During
hat period,  positive  experiences  by  the  operators  led  to
apid enrolment.  By  March  2009,  enrolment  of  patients  in
he non-surgical  study  arm  was  completed  and  by  August
009 enrolment  in  the  operable  arm  was  completed  as
ell. Subsequently,  Edwards  Lifesciences  has  received
DA approval  for  non-randomized  continued  access  to  the
dwards SAPIEN  valve  for  actively  enrolling  PARTNER  sites.
r
t
iD.  Dvir  et  al.
One of  the  points  of  strength  in  the  PARTNER  trial
ethodology was  the  use  of  web-based  conference
alls, conducted  by  the  executive  committee,  to  further
eview and  approve  the  selection  of  each  patient  before
andomization. Every case  was  reviewed  by  executive
ommittee  members,  including  relevant  imaging  studies.  A
otal of  3105  symptomatic  severe  AS  patients  were  screened
t the  investigator  sites  for  enrolment  eligibility  and  1094
ere presented  at  those  conference  calls.  A  total  of  145
ases (13.2%)  were  rejected  during  these  presentations
nd 21  cases  changed  their  cohort  or  access  designation
fter review  (1.8%).  Overall,  34%  of  the  total  number  of
nitially screened  patients  were  ultimately  randomized  in
he PARTNER  trial  (22%  to  the  cohort  A  and  12%  to  cohort
). These  presentations  have  added  power  to  the  study
y enrolling  a  homogenous  population,  and  the  discussion
uring these  meetings  helped  to  disseminate  knowledge
nd catheterization  techniques  between  sites.  It  is  now
bvious that  appropriate  patient  selection  is  one  of  the  most
ifﬁcult  tasks  in  a  TAVR  programme  and  the  presentation
ethodology used  in  the  PARTNER  trial  allowed  support  for
nexperienced sites  to  avoid  beginners’  mistakes.
In  September  2010,  the  results  of  PARTNER  Cohort  B
ere published  [2].  This  was  a  true  milestone  in  the  ﬁeld  of
AVR. For  the  ﬁrst  time,  the  cardiology  community  had  solid
cientiﬁc evidence  based  on  a  randomized  trial  showing
he advantage  of  this  technique  in  patients  with  severe
S who  were  not  candidates  for  surgery.  In  358  inoperable
evere AS  patients,  TAVR,  compared  with  standard  therapy,
igniﬁcantly reduced  the  rates  of  death  from  any  cause,
he composite  endpoint  of  death  from  any  cause  or  repeat
ospitalization, and  cardiac  symptoms,  despite  the  higher
ncidence of  major  strokes  and  major  vascular  events.  As
 result,  TAVR  has  become  the  new  standard  of  care  for
atients with  AS  who  are  not  suitable  candidates  for  surgery.
Six  months  later,  the  results  of  PARTNER  Cohort  A  were
ublished [3].  That  trial  compared  outcomes  after  treat-
ent with  either  the  Edwards  SAPIEN  valve  or  traditional
pen-heart surgery  in  high-risk  operable  patients.  The  study
as a  ‘non-inferiority’  trial  designed  to  evaluate  whether
atient outcomes  after  TAVR  with  the  Edwards  SAPIEN
alve are  similar  to  surgical  outcomes.  The  study  achieved
ts primary  endpoint  at  1  year,  concluding  that  survival  of
atients treated  with  the  Edwards  SAPIEN  transcatheter
ortic valve  was  equivalent  to  survival  of  those  treated
ith SAVR.  In  patients  with  AS  at  high-risk  for  surgery,  TAVR
as non-inferior  to  SAVR  for  all-cause  mortality  at  1  year.
n addition,  mortality  at  30  days  was  lower  than  expected
n both  arms  of  the  trial.  Even  with  this  early-generation
evice and  limited  operator  experience,  the  TAVR  mortality
ate was  the  lowest  reported  in  any  multicentre  series  of
linical data  for  the  Edwards  SAPIEN  valve.
ood and Drug Administration (FDA)
pproval  of the Edwards SAPIEN deviceeviewed the  Edwards  SAPIEN  premarket  approval  applica-
ion [4].  For  the  purpose  of  the  application,  only  patients
n the  inoperable  cohort  (Cohort  B),  who  were  randomized
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formance goal  derived  from  contemporary  studies.  Further-Transcatheter  aortic  valve  replacement  in  the  USA  
to  standard  therapy  versus  TAVR,  were  submitted  and  sub-
sequently presented  to  the  FDA  for  device  approval.  The
FDA did  not  accept  for  evaluation  any  data  from  outside  the
USA. In  their  opinion,  while  various  data  had  been  accumu-
lated from  European  registries,  these  data  originated  from
non-randomized studies  with  endpoints  that  were  less  strin-
gently monitored.  An  extensive  discussion  on  the  analysis
and implications  of  neurological  outcomes  was  undertaken
due to  the  high  stroke  rates  in  the  PARTNER  trial.  The
Panel acknowledged  that  neurological  adverse  events  had
emerged as  a  major  safety  concern  in  the  PARTNER  trial,
which was  among  the  major  concerns  in  approving  the
device.
The majority  of  Panel  members  agreed  that  the  dis-
cussed device  and  procedure  were  effective  in  lowering
mortality in  the  speciﬁc  population  studied.  However,  stroke
rates among  treated  patients  emerged  as  major  issues,
avoiding ‘indication  drift’  in  the  device  usage  by  tight
postapproval monitoring.  The  Panel  voted  to  recommend
approval of  the  Edwards  SAPIEN  transcatheter  heart  valve
for the  treatment  of  certain  inoperable  patients  based  on
data from  the  inoperable  cohort  of  the  PARTNER  trial.  The
approved indication  of  use  stated:  ‘The  Edwards  SAPIEN
transcatheter heart  valve  sizes  23  mm  and  26  mm  and
RetroFlex 3  Delivery  System  are  indicated  for  transfemoral
delivery in  patients  with  severe  symptomatic  native  valve
AS who  have  been  determined  by  a  cardiac  surgeon  to  be
inoperable for  SAVR  and  in  whom  existing  comorbidities
would  not  preclude  the  expected  beneﬁt  from  correction
of the  AS’.
Two postapproval  studies  (PASs)  were  requested  by  the
FDA, pending  device  approval,  with  the  aim  of  assessing
long-term safety  and  effectiveness,  as  well  as  adherence  to
indication of  SAPIEN  utilization.  PAS-1  will  continue  clinical
and echocardiographic  follow-up  on  an  annual  basis  and  will
monitor the  incidence  of  clinical  events  for  all  previously
enrolled patients  in  Cohort  B  of  the  PARTNER  trial,  as  well  as
for the  continuous  access  patients.  PAS-2  will  be  an  obser-
vational controlled  prospective  trial  with  a  non-inferiority
design and  consecutive  patient  enrolment  (n  =  750)  from  a
random sample  (n  =  75)  of  new  sites  previously  selected  by
the Sponsor  (n  =  200).  The  proposed  endpoints  of  this  non-
inferiority study  will  capture  all  neurological  events,  major
vascular events,  major  bleeding,  learning-curve  assessment,
valve durability  to  5  years  and  quality  of  life  measures  to
5 years.  In  November  2011,  Edwards  Lifesciences  received
FDA approval  for  the  Edwards  SAPIEN  device,  which  was  the
ﬁrst USA  commercial  approval  for  a  transcatheter  device
enabling TAVR.  The  criticism  could  be  made  that  this  FDA
approval more  than  4  years  after  the  Conformité  Européenne
(CE) approval  for  European  commercial  sales  of  the
Edwards SAPIEN  transcatheter  aortic  heart  valve  technology
(September 2007)  was  a  result  of  the  strict  FDA  regula-
tions. Nevertheless,  this  method  has  created  the  PARTNER
trial.
After approval  of  the  Edwards  SAPIEN  device  for  commer-
cial use,  the  American  College  of  Cardiology  and  the  Society
of Thoracic  Surgeons  made  a  breakthrough  decision  to  col-
laborate  and  initiated  a  postmarket  Registry  of  all  TAVR
procedures performed  in  the  USA.  This  will  allow  for  con-
tinued outstanding  scientiﬁc  and  regulatory  data  analysis,
which will  facilitate  optimal  utilization  of  TAVR  in  patients
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ith  AS.  The  FDA  has  mandated  that  all  TAVR  patients  be
nrolled in  this  Registry.
he PARTNER (Placement of AoRTic
raNscathetER  valves) II trial
uring  the  last  year,  the  FDA  conditionally  approved  the
rst of  two  planned  cohorts  of  the  randomized  controlled
ARTNER II  trial.  The  ﬁrst  cohort  of  the  PARTNER  II  trial
Cohort B)  will  study  the  next-generation  Edwards  SAPIEN
T transcatheter  heart  valve.  This  trial  includes  the
ow-proﬁle NovaFlex  transfemoral  delivery  system,  which
roadens the  number  of  eligible  patients;  the  trial  will
tudy up  to  450  patients.  A  second  patient  cohort  (Cohort
) will  compare  traditional  open-heart  surgery  with  the
dwards SAPIEN  XT  valve  delivered  either  transfemorally
r transapically.  This  cohort  is  a  non-inferiority  study  of  up
o 2000  patients  with  severe  symptomatic  AS  who  have  an
levated risk  for  traditional  open-heart  surgery  (Society  of
horacic Surgeons  score  >  4),  which  is  a  lower  risk  proﬁle
han that  of  those  who  were  enrolled  in  the  PARTNER  trial.
atients will  be  evenly  randomized  to  receive  the  Edwards
APIEN XT  valve  or  surgery.  Those  undergoing  TAVR  will  be
reated either  transfemorally  or  transapically.  The  primary
ndpoint to  be  evaluated  is  a  composite  of  death  and  major
troke at  2  years,  with  secondary  endpoints  that  include
alve performance  and  quality  of  life  indicators.
valuation of the CoreValve device in the
nited  States of America (USA)
n  April  2009,  Medtronic  (Minneapolis,  MN,  USA)  completed
he acquisition  of  CoreValve  Inc.  This  system,  with  self-
xpandable valve  technology,  received  CE  approval  in  March
007. A  year  later,  in  October  2010,  the  FDA  approved  the
valuation of  the  CoreValve  system  with  the  AccuTrakTM sta-
ility layer  in  two  independent  studies.  Together,  the  two
tudies will  enrol  more  than  1300  patients  at  40  clinical
ites in  the  USA.  Patients  considered  at  high  surgical  risk
re randomized  one-to-one  to  either  TAVR  with  CoreValve
r SAVR.  The  primary  endpoint  for  this  trial  is  freedom  from
ll-cause mortality  at  12  months.  Study  participants  deemed
t extreme-risk  (i.e.  inoperable)  for  SAVR  were  at  ﬁrst  ran-
omized two-to-one  to  receive  either  TAVR  with  CoreValve
r optimal  medical  management.  Shortly  thereafter,  a  con-
itional approval  from  the  FDA  to  modify  the  CoreValve
S Pivotal  Clinical  Trial  was  given.  In  the  revised  design,
he trial  will  assess  the  CoreValve  System  in  extreme-risk
atients in  a  single-arm  study  with  a  primary  endpoint  of
ll-cause death  or  major  stroke  within  12  months.  Patients
eemed at  extreme-risk  will  not  be  randomized  to  optimal
edical management,  where  outcomes  for  these  patients
ave been  shown  in  the  PARTNER  trial  to  be  signiﬁcantly
orse than  for  those  treated  with  transcatheter  valves.
ather, this  patient  group  will  be  evaluated  against  a  per-ore, the  revision  included  the  evaluation  of  alternative
mplantation routes  for  delivering  the  transcatheter  valve,
uch as  the  subclavian  approach.  This  trial  has  coprimary
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ndpoints:  all-cause  death  or  major  stroke  occurring  within
 minimum  of  12  months  of  follow-up  and  a  composite  of
ll-cause death,  major  stroke,  days  of  hospitalization  for
ortic valve  disease  and  number  of  hospitalizations  for  aor-
ic valve  disease  occurring  within  a  minimum  of  12  months
f follow-up.  In  December  2010,  the  Medtronic  CoreValve
S Pivotal  Clinical  Trial  began.  The  ﬁrst  CoreValve  proce-
ure in  the  USA  was  performed  by  Dr.  David  H.  Adams  and
r. Samin  K.  Sharma  at  the  Mount  Sinai  Medical  Center  in
ew York,  NY.  In  January  2012,  enrolment  for  the  extreme-
isk arm  of  the  CoreValve  US  Pivotal  Clinical  Trial  was
nalized.
onclusion
n  conclusion,  it  is  clear  that  the  penetration  rate  of  devices
n general,  and  in  TAVR  speciﬁcally,  is  signiﬁcantly  delayed
n the  USA  compared  with  in  Europe.  This  is  mostly  due
o the  mission  statement  of  the  regulatory  agencies  in  the
SA, which  requires  very  rigorous  clinical  testing  of  a  device
rior to  its  approval.  These  requirements  pose  a  heavy  ﬁnan-
ial burden  on  companies  and  may  delay  expansion  of  the
echnology to  all  patients.  This  methodology,  however,  has
nabled  clinicians  inside  and  outside  the  USA  to  form  aD.  Dvir  et  al.
oncise  scientiﬁcally-based  assessment  of  the  performance
f TAVR  devices  in  terms  of  safety  and  efﬁcacy.
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